. 2014 Mar;11(1):20–33. doi: 10.7497/j.issn.2095-3941.2014.01.002

Table 1. FDA-approved mAbs for use in oncology.

Name	Marketed by	Class	Target	First approved indication	Reported mechanisms of action	Approval year
Rituximab (Rituxan)	Biogen Idec/Genentech	Chimeric IgG1	CD20	Non-Hodgkin’s Lymphoma	ADCC, CDC, Induction of Apoptosis⁴	1997
Trastuzumab (Herceptin)	Genentech	Humanized IgG1	HER2	Breast Cancer	Signal Inhibition, ADCC⁵	1998
Alemtuzumab (Campath)	Sanofi-Aventis	Humanized IgG1	CD52	B cell Chronic Lymphocytic Leukemia	CDC, Induction of Apoptosis⁶	2001
Ibritumomab tiuxetan (Zevalin)	Biogen Idec	Murine IgG1	CD20	Non-Hodgkin’s Lymphoma	Radioisotope Delivery (⁹⁰Y)	2002
Tositumomab (Bexxar)	GlaxoSmithKline	Murine IgG2a	CD20	Non-Hodgkin’s Lymphoma	Radioisotope Delivery (¹³¹I), ADCC, CDC, Induction of Apoptosis⁷	2003
Cetuximab (Erbitux)	Bristol-Myers Squibb/Eli Lilly	Chimeric IgG1	EGFR	Squamous Cell Carcinoma of the Head and Neck	Signal Inhibition, ADCC, CDC⁸	2004
Bevacizumab (Avastin)	Genentech	Humanized IgG1	VEGF	Colorectal Cancer	Signal Inhibition⁹	2004
Panitumumab (Vectibix)	Amgen	Human IgG2	EGFR	Colorectal Cancer	Signal Inhibition, ADCC¹⁰	2006
Ofatumumab (Arzerra)	Genmab/GSK	Human IgG1	CD20	Chronic Lymphocytic Leukemia	ADCC, CDC¹¹	2009
Denosumab (Xgeva)	Amgen	Human IgG2	RANKL	Bone Metastases	Signal Inhibition	2010
Ipilimumab (Yervoy)	Bristol-Myers Squibb	Human IgG1	CTLA-4	Metastatic Melanoma	Signal Inhibition¹²	2011
Brentuximab vedotin (Adcetris)	Seattle Genetics	Chimeric IgG1	CD30	Hodgkin Lymphoma	ADC	2011
Pertuzumab (Perjeta)	Genentech	Humanized IgG1	HER2	Breast Cancer	Signal Inhibition, ADCC¹³	2012
Trastuzumab emtansine (Kadcyla)	Genentech	Humanized IgG1	HER2	Breast Cancer	ADC, Signal Inhibition, ADCC¹⁴	2013